

The Trump administration unveiled its “Great Healthcare Plan,” calling on Congress to codify drug pricing deals and expand health savings accounts, but analysts were skeptical about its impact.
Spencer Perlman of Veda Partners said the proposal appears designed to show action on affordability, yet most elements face long odds in Congress or would have limited effect if enacted. Markets reacted unevenly, with health insurers rallying while several major drugmakers’ shares fell.
This excerpt and any accompanying media (including audio, video, or images) are shared under the principles of fair use, for informational and archival purposes only. All rights remain with the original publisher.